menu
    • menu
    [{"orgOrder":0,"company":"Novasep","sponsor":"Sensorion","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"OTOF-GT","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Novasep","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Novasep \/ Sensorion","highestDevelopmentStatusID":"4","companyTruncated":"Novasep \/ Sensorion"},{"orgOrder":0,"company":"Novasep","sponsor":"Celladon","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"AAV1-based Therapy","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novasep","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Novasep \/ Celladon","highestDevelopmentStatusID":"8","companyTruncated":"Novasep \/ Celladon"},{"orgOrder":0,"company":"Novasep","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Novasep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novasep \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Novasep \/ Exelixis"}]

    Find Clinical Drug Pipeline Developments & Deals by Novasep

    Menu

    Novasep

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novasep

                            Germany
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV1-based Therapy

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Celladon

                            Deal Size : $5.4 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Novasep Signs €4.7m Biomanufacturing Deal with Biotech

                            Details : Through the agreement, Novasep will support Celladon’s plans to produce Mydicar, which is being evaluated in the mid-stage clinical trial for the treatment of heart failure.

                            Brand Name : Mydicar

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 13, 2023

                            Lead Product(s) : AAV1-based Therapy

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Celladon

                            Deal Size : $5.4 million

                            Deal Type : Agreement

                            Axplora Novasep

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novasep

                            Germany
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XB002,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Exelixis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Novasep Secures Manufacturing Deal with US Biotech for ADC Drug Candidate

                            Details : Through the agreement, Novosep will perform the process development of the XB002 ADC. which is being evaluated in the early-stage clinical trial studies for the treatment of non-small cell lung cancer and cervical cancer.

                            Brand Name : XB002

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 07, 2021

                            Lead Product(s) : XB002,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Exelixis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Axplora Novasep

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Novasep

                            Germany
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OTOF-GT

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Preclinical

                            Sponsor : Sensorion

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sensorion and Novasep Sign Agreement

                            Details : The agreement aims for the manufacturing of adeno-associated virus (AAV) vectors, covering the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein and aims to restore the expression of Otoferlin.

                            Brand Name : OTOF-GT

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 11, 2020

                            Lead Product(s) : OTOF-GT

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Preclinical

                            Sponsor : Sensorion

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Axplora Novasep

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth